United States — Food and Drug Administration & Caris Life Sciences

United States — Food and Drug Administration: The United States — Food and Drug Administration's delayed clearance for TriNav Advance is cited by Caris Life Sciences as a reason for its reduced revenue guidance.

Caris Life Sciences: Caris Life Sciences is under investigation for allegedly issuing false and/or misleading statements and failing to disclose pertinent information to investors, leading to a decline in its stock price and a cut in revenue guidance.

United States — Food and Drug Administration: The United States — Food and Drug Administration is expediting the review of daraxonrasib and has allowed expanded access to the drug, indicating its critical role in bringing this new treatment to patients.

Caris Life Sciences: Caris Life Sciences' chief medical officer, George Sledge, provided expert commentary on the significance of Daraxonrasib's breakthrough in targeting the KRAS mutation.